Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GRCE OTCMKTS:IMUC NASDAQ:IPSC NASDAQ:PEPG On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGRCEGrace Therapeutics$3.07-2.5%$3.15$1.75▼$4.97$43.56M1.0694,617 shs64,568 shsIMUCEOM Pharmaceutical$0.08-11.3%$0.08$0.01▼$0.21$11.23M0.0614,703 shs375 shsIPSCCentury Therapeutics$0.50-0.7%$0.55$0.34▼$1.86$43.26M1.78600,457 shs273,398 shsPEPGPepGen$1.59+7.4%$1.30$0.88▼$10.06$48.54M1.18356,387 shs578,948 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGRCEGrace Therapeutics0.00%-1.56%-3.37%+9.00%+314,999,900.00%IMUCEOM Pharmaceutical0.00%+16.08%+21.98%-15.27%-35.65%IPSCCentury Therapeutics0.00%-0.77%-10.86%-13.66%-68.70%PEPGPepGen0.00%+5.71%+14.73%-0.67%-84.39%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGRCEGrace Therapeutics$3.07-2.5%$3.15$1.75▼$4.97$43.56M1.0694,617 shs64,568 shsIMUCEOM Pharmaceutical$0.08-11.3%$0.08$0.01▼$0.21$11.23M0.0614,703 shs375 shsIPSCCentury Therapeutics$0.50-0.7%$0.55$0.34▼$1.86$43.26M1.78600,457 shs273,398 shsPEPGPepGen$1.59+7.4%$1.30$0.88▼$10.06$48.54M1.18356,387 shs578,948 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGRCEGrace Therapeutics0.00%-1.56%-3.37%+9.00%+314,999,900.00%IMUCEOM Pharmaceutical0.00%+16.08%+21.98%-15.27%-35.65%IPSCCentury Therapeutics0.00%-0.77%-10.86%-13.66%-68.70%PEPGPepGen0.00%+5.71%+14.73%-0.67%-84.39%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGRCEGrace Therapeutics 3.00Buy$12.00290.88% UpsideIMUCEOM Pharmaceutical 0.00N/AN/AN/AIPSCCentury Therapeutics 3.00Buy$3.75654.22% UpsidePEPGPepGen 2.50Moderate Buy$7.25355.97% UpsideCurrent Analyst Ratings BreakdownLatest IMUC, IPSC, GRCE, and PEPG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/9/2025PEPGPepGenGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$6.00(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGRCEGrace TherapeuticsN/AN/AN/AN/A$4.86 per shareN/AIMUCEOM PharmaceuticalN/AN/AN/AN/AN/AN/AIPSCCentury Therapeutics$6.59M6.52N/AN/A$1.90 per share0.26PEPGPepGenN/AN/AN/AN/A$3.64 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGRCEGrace Therapeutics-$9.57M-$0.86N/AN/AN/AN/A-20.36%-18.09%11/12/2025 (Estimated)IMUCEOM Pharmaceutical-$1.89MN/A0.00∞N/AN/AN/AN/AN/AIPSCCentury Therapeutics-$126.57M-$0.29N/AN/AN/A-19.10%-11.53%-6.94%11/4/2025 (Estimated)PEPGPepGen-$89.98M-$2.96N/AN/AN/AN/A-92.51%-70.39%11/6/2025 (Estimated)Latest IMUC, IPSC, GRCE, and PEPG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025IPSCCentury Therapeutics-$0.38-$0.38N/A-$0.38$0.03 millionN/A8/12/2025Q1 2026GRCEGrace Therapeutics-$0.22-$0.21+$0.01-$0.21N/AN/A8/7/2025Q2 2025PEPGPepGen-$0.85-$0.70+$0.15-$0.70N/AN/A6/20/2025Q4 2025GRCEGrace Therapeutics-$0.23-$0.21+$0.02$0.01N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGRCEGrace TherapeuticsN/AN/AN/AN/AN/AIMUCEOM PharmaceuticalN/AN/AN/AN/AN/AIPSCCentury TherapeuticsN/AN/AN/AN/AN/APEPGPepGenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGRCEGrace TherapeuticsN/A8.878.87IMUCEOM PharmaceuticalN/AN/AN/AIPSCCentury TherapeuticsN/A10.7210.72PEPGPepGenN/A4.744.74Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGRCEGrace Therapeutics6.08%IMUCEOM PharmaceuticalN/AIPSCCentury Therapeutics50.20%PEPGPepGen58.01%Insider OwnershipCompanyInsider OwnershipGRCEGrace Therapeutics11.10%IMUCEOM Pharmaceutical3.28%IPSCCentury Therapeutics5.00%PEPGPepGen4.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGRCEGrace TherapeuticsN/A13.83 million12.29 millionN/AIMUCEOM Pharmaceutical3126.50 million122.35 millionNot OptionableIPSCCentury Therapeutics17086.39 million82.07 millionOptionablePEPGPepGen3032.80 million31.29 millionNot OptionableIMUC, IPSC, GRCE, and PEPG HeadlinesRecent News About These CompaniesGuggenheim Initiates Coverage of PepGen (PEPG) with Buy RecommendationSeptember 10, 2025 | msn.comPepGen (NASDAQ:PEPG) Now Covered by Analysts at GuggenheimSeptember 10, 2025 | americanbankingnews.comPepGen initiated with a Buy at GuggenheimSeptember 9, 2025 | msn.comFINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of PepGenAugust 11, 2025 | businesswire.comFaruqi & Faruqi Reminds PepGen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 11, 2025 - PEPGAugust 9, 2025 | prnewswire.comLevi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of PepGen Inc.(PEPG) ShareholdersAugust 8, 2025 | globenewswire.comPepGen Reports Second Quarter 2025 Financial Results and Recent Corporate HighlightsAugust 8, 2025 | finance.yahoo.comPepGen Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before August 8, 2025 to Discuss Your Rights - PEPGAugust 8, 2025 | prnewswire.comPEPGEN (PEPG) FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds PepGen Investors of the August 8th Deadline and Encourages Investors to Contact the FirmAugust 7, 2025 | globenewswire.comLost Money on PepGen Inc. (PEPG)? Join Class Action Suit Seeking Recovery – Contact The Gross Law FirmAugust 7, 2025 | globenewswire.comPepGen Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. August 8, 2025 Deadline to file Lead Plaintiff Motion.August 7, 2025 | globenewswire.comPEPG INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that PepGen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitAugust 7, 2025 | globenewswire.comPEPG Investors Have Opportunity to Lead PepGen Inc. Securities Fraud Lawsuit with the Schall Law FirmAugust 7, 2025 | prnewswire.comPEPG DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages PepGen Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 8 Deadline in Securities Class Action – PEPGAugust 6, 2025 | globenewswire.comPomerantz Law Firm Announces the Filing of a Class Action Against PepGen Inc. and Certain Officers - PEPGAugust 6, 2025 | prnewswire.comPEPGEN (PEPG) URGENT DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds PepGen Investors of the August 8th Deadline and Encourages Investors to Contact the FirmAugust 5, 2025 | globenewswire.comPepGen Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; August 8, 2025 Deadline to file Lead Plaintiff MotionAugust 5, 2025 | globenewswire.comLevi & Korsinsky Notifies PepGen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – PEPGAugust 5, 2025 | globenewswire.comPomerantz Law Firm Announces the Filing of a Class Action Against PepGen Inc. and Certain Officers – PEPGAugust 5, 2025 | globenewswire.comDEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of PepGenAugust 5, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIMUC, IPSC, GRCE, and PEPG Company DescriptionsGrace Therapeutics NASDAQ:GRCE$3.07 -0.08 (-2.54%) As of 04:00 PM EasternGrace Therapeutics Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton, New Jersey.EOM Pharmaceutical OTCMKTS:IMUC$0.08 -0.01 (-11.26%) As of 11:15 AM EasternImmunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey.Century Therapeutics NASDAQ:IPSC$0.50 0.00 (-0.72%) Closing price 04:00 PM EasternExtended Trading$0.50 +0.00 (+0.16%) As of 06:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.PepGen NASDAQ:PEPG$1.59 +0.11 (+7.43%) Closing price 04:00 PM EasternExtended Trading$1.65 +0.06 (+4.03%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Reddit Hits Record Highs: Why Wall Street Is Taking Notice Royal Caribbean's 33% Dividend Hike Signals Deeper Growth FuelCell Energy's Stock: Is a Fundamental Breakout Underway? After a Strong Wall Street Debut, Klarna's Real Work Begins MarketBeat Week in Review – 09/08 - 09/12 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
